SLC5A2 and chronic kidney disease: The predicted 3 year absolute risk reduction (\documentclass[12pt]{minimal}\usepackage{amsmath}\usepackage{wasysym}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{amsbsy}\usepackage{mathrsfs}\usepackage{upgreek}\setlength{\oddsidemargin}{-69pt}\begin{document}$$pARR$$\end{document}pARR) for SGLT2 inhibitors, estimated by integrating the relative treatment effect from the SGLT2 inhibitor trial meta-analysis (HR 0.62) with the CKD-PC risk score, showed good calibration accuracy (Fig. 2), with a calibration slope of 1.10 (95% CI 1.09, 1.12).